Exelixis | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.23B 93.19M 2025-06
Agios Pharmaceuticals USD 1.47B 84.28M 2025-06
Amgen USD 87.9B 1.47B 2025-06
AstraZeneca USD 112.42B 6.17B 2025-06
Bayer EUR 105.24B 3.95B 2025-06
BioMarin Pharmaceutical USD 7.46B 309.33M 2025-06
Bristol-Myers Squibb USD 94.68B 2.25B 2025-06
Cytokinetics USD 1.23B 38.42M 2025-06
Eisai JPY 1.41T 23.07B 2025-06
Eli Lilly USD 100.92B 11.53B 2025-06
Exelixis USD 2.68B 159.17M 2025-07
Genmab DKK 6.46B 122M 2025-06
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Incyte USD 5.82B 71.99M 2025-06
Ionis Pharmaceuticals USD 2.99B 172.18M 2025-06
MacroGenics USD 261.65M 2.84M 2024-12
Merck USD 117.52B 2.4B 2025-06
Moderna USD 12.01B 694M 2025-06
Neurocrine Biosciences USD 3.89B 202.1M 2025-06
Novartis USD 104.4B 4.45B 2025-06
Pfizer USD 206.1B 1.93B 2025-06
Sanofi 132.8B 3.04B 2024-12
Takeda JPY 14T 243.81B 2025-06
Ultragenyx Pharmaceutical USD 1.31B 5.66M 2025-06
Xencor USD 879.42M 25.26M 2025-06


Exelixis Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.